Dgki methylation status modulates the prognostic value of mgmt in glioblastoma patients treated with combined radio-chemotherapy with temozolomide

HIGHLIGHTS

• who: Amandine Etcheverry and colleagues from the 75/CNRS UMR, Université Pierre-et-Marie-Curie, Institut du Cerveau et la Moelle Épinière, Groupe Pitié-Salpêtrière, Paris, FranceEditor: Marta MAlonso, University Hospital of Navarra, Spain have published the paper: DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide, in the Journal: PLOS ONE | www.plosone.org of September/18,/2014
• what: The authors aimed to integrate biological and clinical prognostic factors into a nomogram intended to predict the survival time of an . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.